<DOC>
	<DOCNO>NCT01160614</DOCNO>
	<brief_summary>The purpose study characterize pharmacokinetics ( PK ) single-dose ORF tablet pediatric patient age 6 16 year , inclusive .</brief_summary>
	<brief_title>Pharmacokinetics Safety ORF Tablets Pediatric Patients</brief_title>
	<detailed_description />
	<mesh_term>Oxycodone</mesh_term>
	<criteria>Written inform consent provide parent legal guardian patient assent , appropriate . Children either gender , age 6 16 year , inclusive . Have expect moderate severe pain extended period time require inpatient opioid analgesic treatment least 12 hour minimum duration study period treatment . In order receive first oral dose , patient must respiratory stability , include sustain SpO2 least 92 % without supplemental oxygen 15 minute period prior dose . Must inpatient treatment period study . The patient 's anticipated opioid analgesic requirement first 12 hour follow administration ORF must equivalent least 10 mg intravenous ( IV ) morphine . Have adequate pain control 6 hour prior study drug administration , base appropriate clinical assessment . Must sufficiently alert communicate complete face pain scalesrevised ( FPSR ) 100mm visual analogue scale ( VAS ) . Females child bear potential must use adequate reliable method contraception ( e.g. , barrier additional spermicidal foam jelly , intrauterine device , hormonal contraception ) abstinent . If female , must negative pregnancy test nonlactating . Must able swallow tablet whole . Must stable vital sign . Must vascular access facilitate blood draw . Must willing able participate aspect study involve use oral medication , patient evaluation , phlebotomy , evidence write informed consent parent legal guardian write patient assent require local IRB/EC . Must willing 10 milliliter ( mL ) blood collect blood analysis ( 7 mL primary PK 3 mL secondary PK analysis ) ; 10 mL blood prespecified safety laboratory test , without safety concern . Must treat opioid minimum 96 hour prior first dose ORF . Any history hypersensitivity medical contraindication use oxycodone ( exclude patient history expect opioidrelated adverse event ( AEs ) , lightheadedness , dizziness , sedation , nausea , vomit ) . Any current history medical surgical condition might significantly interfere gastrointestinal absorption , distribution , metabolism , excretion oxycodone ( include history serious disease+ gastrointestinal tract , liver , kidney , and/or bloodforming organ ) . Received oxycodone 24 hour prior study drug administration . . Received epidural ( regional ) anesthesia &lt; 12 hour prior first oral dose ORF . A current history malabsorption syndrome . A current diagnosis sleep apnea within last year . Reduced renal function ( serum creatinine &gt; 1.8 X upper limit normal age ) . Hepatic impairment evidence serum alanine amino transferase ( ALT ) serum aspartate amino transferase ( AST ) &gt; 5 time upper limit normal ( ULN ) age . Currently take medication CYP3A4 inhibitor . Impaired respiratory reserve include severe acute chronic lung disease , patient receive mechanical respiratory support , include mechanical ventilation , BIPAP , CPAP 6 hour prior first oral dose entire oral treatment period . Impaired cardiovascular stability ( e.g. , day surgery cardiac surgery patient ) . Participated clinical drug study within 30 day precede initial dose study . Patients surgery within 96 hour prior day first dose study drug . Deemed unsuitable investigator reason ( ) specifically state exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Pediatric</keyword>
	<keyword>Post-operative</keyword>
	<keyword>Nonsurgical</keyword>
	<keyword>patient</keyword>
	<keyword>Opioid</keyword>
</DOC>